Simeon George bought $51M of CRSP
director at CRISPR Therapeutics AG. 989,812 shares at an average of $52.03, traded Jul 16, 2025, filed Jul 17, 2025.
Score components
- +15RoleDirector
- +25Trade size$51.5M at market
- +10Relative to holdingsHoldings up 1567%
- 0Price contextNear the top of the 52-week range
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-096666, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 16, 2025 | POpen-market purchase Common Sharesindirect: See Note 1 | +6,510 | $52.03 | $339k | 69,687 | Jul 17, 2025 |
| Jul 16, 2025 | POpen-market purchase Common Sharesindirect: See Note 2 | +22,319 | $52.03 | $1.2M | 238,897 | Jul 17, 2025 |
| Jul 16, 2025 | POpen-market purchase Common Sharesindirect: See Note 3 | +960,983 | $52.03 | $50M | 1,730,179 | Jul 17, 2025 |
Related signals
Other insiders at CRISPR Therapeutics AG and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $119k 1,990 shares | -2% | |
| 8Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $626k 10,400 shares | -10% | |
| 40Moderate | CRISPR Therapeutics AG | Ali Behbahani director | $781k 13,679 shares | -45% | |
| 32Weak | CRSPsell CRISPR Therapeutics AG | Samarth Kulkarni Chief Executive Officer | $761k 13,081 shares | -6% | |
| 54Moderate | CRSPbuy CRISPR Therapeutics AG | Douglas A Treco director | $1.1M 20,000 shares | +1000% | |
| 21Weak | CRSPsell CRISPR Therapeutics AG | Naimish Patel Chief Medical Officer | $141k 3,932 shares | -39% | |
| 33Weak | CRISPR Therapeutics AG | Julianne Bruno Chief Operating Officer | $71k 1,714 shares | -14% | |
| 26Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $131k 3,185 shares | -4% | |
| 36Weak | CRISPR Therapeutics AG | Raju Prasad Chief Financial Officer | $91k 2,197 shares | -12% | |
| 41Moderate | CRISPR Therapeutics AG | Samarth Kulkarni Chief Executive Officer | $414k 10,031 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.